A recent trial compared the efficacy of standard oral therapy for pulmonary TB with a dry powder inhaler containing fixed doses of isoniazid, rifampicin, pyrazinamide, and levofloxacin.
Researchers compared clinical outcomes of single vs double antipseudomonal antibiotics used to treat pulmonary exacerbations in patients with cystic fibrosis.
In this study, we found that early first antibiotic administration was associated with improved outcomes in ED patients with septic shock using propensity score analysis.
A new scoring system for Drug Resistance in Pneumonia (DRIP) has demonstrated efficacy in improving pneumonia-related prescription trends, including a significant drop in broad-spectrum antibiotic prescriptions.
Data from the Generation R, SEATON, PACMAN, and BREATHE studies were analyzed to determine the link between asthma, asthma exacerbations, and childhood antibiotic use.
Approximately 22.1% adults do not respond to initial antibiotic treatment for community-acquired pneumonia, according to new research presented at ATS 2017.
Molecular point-of-care testing for viruses led to more patients receiving single or brief doses of antibiotics without any evidence of increased harm.
The European Respiratory Society and the American Thoracic Society released clinical guidelines for the treatment of patients with chronic obstructive pulmonary disease exacerbations.
Despite current guidelines recommending amoxicillin in most children with community-acquired pneumonia (CAP), macrolides and broad-spectrum antibiotics continue to be prescribed for outpatient CAP.
Switching from intravenous to oral antibiotics in patients with healthcare-associated pneumonia was found to be safe.
